首页> 外文期刊>Cardiovascular Research >HNE-induced 5-LO expression is regulated by NF-{kappa}B/ERK and Sp1/p38 MAPK pathways via EGF receptor in murine macrophages.
【24h】

HNE-induced 5-LO expression is regulated by NF-{kappa}B/ERK and Sp1/p38 MAPK pathways via EGF receptor in murine macrophages.

机译:HNE诱导的5-LO表达受鼠巨噬细胞中NF-κB/ ERK和Sp1 / p38 MAPK途径通过EGF受体的调节。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: 5-Lipoxygenase (5-LO) has been suggested to be a modulator of atherosclerotic plaque instability and co-exists with 4-hydroxynonenal (HNE) in macrophages in atherosclerotic lesions. To determine the potential role for HNE in 5-LO expression, the molecular mechanisms of 5-LO expression were evaluated in HNE-stimulated macrophages. METHODS AND RESULTS: A genomic sequence of the promoter 2.0 kb upstream of the transcription initiation site was amplified, and a series of sequentially deleted fragments were then fused to a luciferase reporter gene. The promoter region 213 bp upstream of the transcription start site was responsible for the HNE-enhanced transcriptional activity of 5-LO. Site-directed mutagenesis of this region showed that the transcription factors, including stimulating protein 1 (Sp1) and nuclear factor-kappaB (NF-kappaB), were associated with up-regulation of HNE-induced 5-LO transcription. Moreover, the role of Sp1 and NF-kappaB in HNE-induced 5-LO expression was confirmed by siRNA knockdown of Sp1 and NF-kappaB. The HNE-enhanced Sp1 and NF-kappaB activities were attenuated by SB203580, a p38 mitogen-activated protein kinase (MAPK) inhibitor, and PD98059, an extracellular signal-regulated kinase (ERK) inhibitor, respectively. In addition, the HNE-enhanced phosphorylation of p38 MAPK and ERK was inhibited by AG1478, an epidermal growth factor receptor (EGFR) antagonist, but not by AG1295, a platelet-derived growth factor receptor (PDGFR) antagonist. CONCLUSION: 5-LO expression by HNE was regulated at the transcriptional level by the EGFR-mediated activation of Sp1/p38 MAPK and NF-kappaB/ERK pathways in macrophages, which may lead to the development of therapeutic interventions for regulating 5-LO expression in atherosclerosis.
机译:目的:5-脂氧合酶(5-LO)被认为是动脉粥样硬化斑块不稳定性的调节剂,并且与4-羟基壬烯醛(HNE)在动脉粥样硬化病变的巨噬细胞中共存。为了确定HNE在5-LO表达中的潜在作用,在HNE刺激的巨噬细胞中评估了5-LO表达的分子机制。方法和结果:扩增了转录起始位点上游2.0 kb启动子的基因组序列,然后将一系列顺序缺失的片段与荧光素酶报道基因融合。转录起始位点上游213 bp的启动子区域负责5-LO的HNE增强转录活性。该区域的定点诱变表明,转录因子,包括刺激蛋白1(Sp1)和核因子-κB(NF-kappaB),与HNE诱导的5-LO转录上调相关。此外,Sp1和NF-kappaB的siRNA敲除证实了Sp1和NF-kappaB在HNE诱导的5-LO表达中的作用。 HNE增强的Sp1和NF-κB活性分别被p38丝裂原活化蛋白激酶(MAPK)抑制剂SB203580和细胞外信号调节激酶(ERK)抑制剂PD98059减弱。此外,表皮生长因子受体(EGFR)拮抗剂AG1478抑制了p38 MAPK和ERK的HNE增强磷酸化,而血小板源性生长因子受体(PDGFR)拮抗剂AG1295则没有抑制。结论:EGFR介导的巨噬细胞中Sp1 / p38 MAPK和NF-kappaB / ERK途径的激活在HNE上调节5-LO表达,这可能导致调节5-LO表达的治疗手段的发展。在动脉粥样硬化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号